Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;21(2 Neuro-oncology):452-75.
doi: 10.1212/01.CON.0000464180.89580.88.

Paraneoplastic disorders

Review

Paraneoplastic disorders

Eric Lancaster. Continuum (Minneap Minn). 2015 Apr.

Abstract

Purpose of review: Paraneoplastic disorders are autoimmune diseases associated with risks for specific cancers and marked by specific autoantibodies. They cause diverse clinical syndromes of the central and peripheral nervous systems.

Recent findings: In the peripheral nervous system, autoimmunity to synaptic or axonal proteins has long been recognized to associate with specific cancers. In these disorders, typified by myasthenia gravis, the antibodies are directly toxic, and recovery with immunotherapy is the rule. In contrast, the classic paraneoplastic syndromes involve a higher risk of cancer, autoantibodies to intracellular proteins (eg, Hu proteins), T-cell-dependent disease mechanisms targeting the CNS or peripheral nervous system, and a poor response to treatment. Following the discovery of N-methyl-D-aspartate (NMDA) receptor antibodies, a new and expanding group of disorders involving autoantibodies to CNS synaptic and neuronal membrane proteins and a favorable response to immunotherapy emerged. A final group of disorders involves antibodies to intracellular synaptic proteins, such as glutamic acid decarboxylase 65 (GAD65), and it is unclear whether these diseases involve antibody or T-cell mechanisms.

Summary: Neurologists should recognize the clinical syndromes associated with paraneoplastic disorders, utilize autoantibody and other testing to confirm the diagnosis, understand the pathologic basis of the diseases, and promptly give appropriate therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cultured rat embryonic hippocampal neurons were immunostained live with CSF of a patient with GAD65 antibodies (green), with nuclei visualized with DAPI (blue), but patients’ antibodies are unable to bind to the neurons (A). Neurons immunostained with the same CSF after these neurons were fixed and permeabilized show reactivity of the CSF with GAD65 (B).
Figure 2
Figure 2
Cells transfected to express a synaptic antigen (in this example Caspr2) were immunostained with patient CSF (in green; A) and a commercial antibody to Caspr2 (in red; B). Merge images show colocalization, with the nuclei of transfected and untransfected cells labeled blue with DAPI (C).
Figure 3
Figure 3
Cultured rat embryonic hippocampal neurons were immunostained live with CSF of a patient with cell surface antibodies (in this case to DNER) (A). The same neurons were immunostaining with a commercial antibody to DNER (B). Merged images demonstrate the colocalization (C).
Case 1 Figure
Case 1 Figure
Brain MRI of a patient with paraneoplastic encephalomyelitis showing increased T2 signal in the medial temporal lobes.
Case 3 Figure
Case 3 Figure
The extreme delta brush EEG pattern.
Case 4
Case 4
Brain MRI of a patient with autoimmune encephalitis, showing involvement of the insular cortex, especially on the left side.

Similar articles

Cited by

References

    1. Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Danko K. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. The Journal of rheumatology. 2008;35:438–444. - PubMed
    1. Ariño HG-AN, Blanco Y, Martínez-Hernández E, Sabater L, Petit-Pedrol M, Rouco I, Bataller L, Dalmau JO, Saiz AGF. Cerebellar Ataxia and Glutamic Acid Decarboxylase Antibodies Immunologic Profile and Long-term Effect of Immunotherapy. JAMA neurology. 2014 Epub June 16, 2011. - PMC - PubMed
    1. Burk K, Wick M, Roth G, Decker P, Voltz R. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. Journal of neurology. 2010;257:59–62. - PubMed
    1. Burton AR, Baquet Z, Eisenbarth GS, Tisch R, Smeyne R, Workman CJ, Vignali DA. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol. 2010;184:4863–4870. - PMC - PubMed
    1. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Annals of neurology. 2001;50:301311. - PubMed

MeSH terms